*

Xingyao Li, Ph.D.

Resume

Contact Information

Name: Xingyao Li, Ph.D.

Position: IRTA fellow, National Institute of Health (NIH) – National Institute of Environmental Health Sciences (NIEHS).

Work address: 111 T.W. Alexander Drive, Durham, NC 27709 Cell phone: 984-***-**** Email: adwsot@r.postjobfree.com

Expertise Summary

15 years (2008-2023) molecular and cellular biologist with core techniques.

10 years (2013-2023) biochemist experience in academic research.

• 3 years postdoctoral training in cancer biomarker with CRISPR or base editing systems, including optimizing media contents for DNA damage, cancer cell stress and metabolism test.

• 6 years IRTA fellow training in NIH, optimization, and development of liposome nanoparticle delivery systems for intracellular delivery of metabolically resistant small molecules, maintenance of key assays, including detection and characterization of cellular exosomal nanoparticles.

9 years (2004-2013) biotech/pharmaceutical experience in R&D techniques.

• 4 years analytical scientist in the pharmaceutical industry for isolation and purification analysis of small molecule compounds in product development and Quality Control (QC) standards development (R&D, Quality Control (QC) standards development, Quantitative analysis by TLC and HPLC).

• 5 years experience in developing and maintaining critical assays for drug discovery, including in vitro anti-tumor cell model and reporter screening assays development for small molecule inhibitors of cell signaling pathways as well as in vitro and in vivo candidate small molecule validation.

Read scientific literature to increase scientific knowledge about current and future projects.

Present research findings in internal and external meetings.

Excellent communication skills, experience in writing and speaking to technical and non- technical audiences.

2

Xingyao Li, Ph.D.

Summary of Accomplishments

Biomarkers and drug discovery

• Identified novel compounds that selectively inhibits colon cancer cell proliferation in vitro and in vivo with implications as potential candidates to improve clinical treatment for colon cancer patients (Li, X., et al. Cell Death Discovery; Li, X., et al. PLoS One).

• Identified cancer biomarkers that activates p53 in response to genotoxicity and points to ATF3 as a potential cancer therapeutic target (Li, X., et al. Cell Death and Differentiation; Li, X., et al. Cell Reports).

• Identified PPIP5K and XPR1 mutations as key biomarkers with pathological impact on disease and suggest potential for drug development targeting XPR1 dysregulation in cancer and ectopic calcification (Li, X., et al. PNAS)

Research and development

• Developed reporter systems and cancer cell line models and collaborated with medicinal chemists for drug discovery resulting in 31 peer-reviewed publications.

• In collaboration with medicinal chemists, developed two novel mixed NH3/amine platinum

(II) complexes, 3-dichloroacetyl cyclobutane-1,1-dicarboxylate, which release platinum- based pharmacophore and dichloroacetic acid, an apoptosis inducer through hydrolysis reaction, thus providing a new avenue for the development of platinum-based drugs that can both overcome drug resistance and selectively target tumor cells.

• In collaboration with medicinal chemists, tested and reported the cell proliferation inhibitory and cytotoxic activities of more than 5,000 compounds in five cancer cell lines, laying the foundation for further molecular structure optimization design and anti-tumor drug development.

• Drug discovery efforts resulted in the granting of 4 drug development patents.

Mentored 3 undergraduate students

• Responsible for hiring, supervision, and performance review of three junior scientists.

• Effectively communicated and transferred complex technical information to junior personnel. Used expertise to assist junior personnel with problem solving.

• Empowered project staff to meet quality standards, use resources effectively and deliver tasks on time.

3

Xingyao Li, Ph.D.

Professional Experience

IRTA fellow 2/2017- present, NIH/NIEHS (supervisor: Stephen B. Shears, Ph.D.)

• Developed liposome nanoparticle delivery system for metabolic resistance small molecules delivery and identified small molecule targets through pharmacological strategies.

• Identified PPIP5K and XPR1 mutations as key biomarkers with pathological impact on disease and suggest potential for drug development targeting XPR1 dysregulation in cancer and ectopic calcification.

Postdoctoral training 11/2013-1/2017, Georgia Cancer Center (supervisor: Chunhong Yan, Ph.D.)

• Identified that p53, MDM2 and ATF3 play distinct roles in tumorigenesis and other physiological/pathological events.

• Identified the oncogenic activity of the ATF3 marker, which could potentially be used to target cancer cells with drug-resistant properties in a serine-restricted environment.

Ph.D. 9/2008-6/2013, University of Chinese Academy of Sciences, China

• I performed 96-well cell-based assays to screen small molecular with proliferation inhibitory and cytotoxic activities in cancer cell lines.

• I generated cell reporter model to screen Wnt signaling inhibitors.

• I performed in vitro and in vivo experiments to validate candidate small molecule drug targets.

Research associate 7/2004-7/2007, CSPC Pharma, China

• I performed chemical isolation and purification for drug development.

• I developed analytical test method (quantitative analysis by TLC and HPLC for product development and Quality Control) for use in process development support and ultimately cGMP testing.

Education

9/2008–6/2013 Ph.D. in Pharmacy, Department of Pharmacology, University of Chinese Academy of Sciences, China. (Advisor: Yan Li, Ph.D.). Thesis:” Identification of Small Molecule Inhibitors of Wnt Signaling Pathway.” Excellent Grades

4

Xingyao Li, Ph.D.

9/2000–6/2004 B.S., Pharmacy, Chengdu University of Traditional Chinese Medicine, China. Experience & Techniques

• Analytical chemistry: column chromatography, isolation and purification of small molecule compounds, quantitative analysis by TLC and HPLC, liposome synthesis and preparation.

• Biochemistry: protein synthesis, protein purification, in vitro cell free extracts, spectroscopy, electrophoresis, western blotting, SDS-PAGE, chemiluminescence luminometry assays, enzyme-linked immunosorbent assay (ELISA), enzyme kinetic assays etc.

• Cell biology: cell culture (bacterial, mammalian), MTT/MTS cell viability assay, cell colony maintenance, flow cytometry, immunofluorescence, siRNA, transfection, stable cell lines generation and maintenance, lysosome/organelle immunoprecipitation, chromatin immunoprecipitation (ChIP) assays, radiolabeled cell uptake and tracing, vascular cell and osteocyte cell calcification, cell differentiation induction, alizarin red s staining assays etc.

• Microscopy: light microscopy, epifluorescence microscopy, confocal microscopy.

• Molecular biology: CRISPR gene editing, gene cloning (site directed mutagenesis - multi- fragment cloning), PCR, quantitative RT-PCR, RNA-seq analysis, gene expression analysis, southern blotting etc.

• Animal techniques: small animal dietary intake, genotyping, xenograft experiments. Team skills

• Participated in lab meeting, exchanged ideas and constructive criticisms.

• Organized collaborations by setting meeting times and agendas, promoting scientific discussions, and ensuring that deadlines were met.

• Integrated a team of 2 biochemists to solve a challenge resulting in a change of procedure that decreased the timeline of the project 3-fold.

• Managed 4 technicians, 3 graduate students, 9 undergraduates and many lab rotations students.

• Participated in hiring new lab personnel.

5

Xingyao Li, Ph.D.

Presentations & Awards

2023 Gordon Research Conference, Physiology, Biology and Pathology of Phosphate, Grand Galvez, Texas, Feb 12 - 17, 2023.

2023 International Inositol Phosphates: The More, the Merrier, Jan 9-11, 2023. 2022 EMBO Workshop, The endoplasmic reticulum: The master regulator of membrane trafficking, Lucca, Italy, Oct 23-28, 2022.

2022 Grant writers’ seminars and workshops- write winning NIH grant proposals, A Virtual Seminar, Feb 22-23, 2022.

2021 International Inositol Phosphate Meeting ("Inositol phosphates, the more the merrier"), Jan 11-14, 2021.

2019 ASCB EMBO 2019 Annual meeting, Washington DC, Dec 7-11, 2019. Abstract 4241: Insp8 Regulates Cellular Phosphate Homeostasis and Calcification. 2018 Keystone Symposia, Novel Aspects of Bone Biology (E3), Snowbird, UT, June 13- 16, Abstract 2028: Regulation of Cellular phosphate Homeostasis by Inositol Pyrophosphates.

2016 AACR Annual Meeting 2020, New Orleans, Louisiana. April 16-20, 2016. Abstract 3683: The stress response mediator ATF3 stabilizes p53 by competing with it for MDM2-mediated ubiquitination.

2012 The 9th IUPAC International Symposium on Chemical Biology and the 8th World Chinese Symposium on Medicinal Chemistry, Beijing, August 25-29, 2012. 2006 Symposium on Innovative Drug R&D and Intellectual Property Protection of China, Beijing, November 1-3, 2006.

Honors & Awards

2023 Registration Award Recipient for the Gordon Conference on the Physiology, Biology and Pathology of Phosphate, USA.

2021 NIH Fellows Award for Research Excellence (FARE), NIH. 6

Xingyao Li, Ph.D.

2019 NIH Fellows Award for Research Excellence (FARE), NIH. 2013 CAS Award for Research Excellence, China.

2010 Graduate Student Professional Development Award, China. 2006 CSPC Pharmacy Award for Outstanding Employees, China. Poster Presentations

2023 Gordon Research Conference, Physiology, Biology and Pathology of Phosphate, Grand Galvez, Texas, Feb 12 - 17, 2023.

2022 EMBO Workshop, The endoplasmic reticulum: The master regulator of membrane trafficking, Lucca, Italy, Oct 23-28, 2022.

2019 ASCB EMBO 2019 Annual meeting, Washington DC, Dec 7-11, 2019. Abstract 4241: Insp8 Regulates Cellular Phosphate Homeostasis and Calcification. 2018 Keystone Symposia, Novel Aspects of Bone Biology (E3), Snowbird, UT, June 13- 16, Abstract 2028: Regulation of Cellular phosphate Homeostasis by Inositol Pyrophosphates.

2016 AACR Annual Meeting 2020, New Orleans, Louisiana. April 16-20, 2016. Abstract 3683: The stress response mediator ATF3 stabilizes p53 by competing with it for MDM2-mediated ubiquitination.

Teaching & Other Experience

2021- present Member of the American Association of Extracellular Vesicles (AAEV). 2016 Member of the American Association for Cancer Research. 2013 CAS Graduate Student Excellent Grades, Abstract Judge. 2012 - 2013 University of Chinese Academy of Sciences, China. Graduate Program. Course topics: Pharmacology and Toxicology of Small Molecules. 2011 - 2013 University of Chinese Academy of Sciences, China. Seminars for pharmacy students. Course topics: Natural Product Medicinal Chemistry and Molecular 7

Xingyao Li, Ph.D.

Pharmacology, High Throughput Drug Screening, Generation of High-Content Drug Screening Model, Evaluation of Biological Activity of Natural Compounds. Professional Services

Journals Reviewer:

• Medicine

• Aging

• PLoS ONE

Patents

1. [Chinese invention patent]: Platinum anticancer complexes with selectivity to cancer cells (2011); Inventors: Liu Weiping; Li Yan; Chen Xizhu; Ye Qingsong; Li Xingyao; Su Jia; Hou Shuqian; Yu Yao; Chang Qiaowen. Patent number: 201010274265.2. 2. [Chinese invention patent]: β-carboline derivatives or pharmaceutically acceptable salts, their preparation methods, and their anti-tumor applications (2014); Inventors: Zhu Huajie; Li Yan; Bai Bing; Li Xingyao. Patent number: CN201310139090.8. 3. [Chinese invention patent]: The application of picariin as Wnt signaling pathway inhibitor and anticancer drug (2014); Inventors: Li Yan; Sun Handong; Pu Jianxin; Li Xingyao; Zhang Haibo. Patent number: CN201310185250.2.

4. [Chinese invention patent]: Application of ciclopirox and ciclopirox amine in the preparation of medicines for the prevention and treatment of melanoma (2014); Inventors: Zhou Hongyu; Li Yan; Kong Lingmei; Yan Juming; Li Xingyao. Patent number: CN201310103668.

Peer Reviewed Publications

Peer-Reviewed Articles (in reverse chronological order) https://scholar.google.com/citations?user=yKiws9EAAAAJ&hl=en

* Co-first author

1. Xingyao Li*, Daniel Gracilla*, Lun Cai, Mingyi Zhang, Xiaolin Yu, Xiaoguang Chen, Junran Zhang, Xiaochun Long, Han-Fei Ding, Chunhong Yan. ATF3 promotes the serine 8

Xingyao Li, Ph.D.

synthesis pathway and tumor growth under dietary serine restriction. Cell Reports, 2021 Sep 21. PMID: 34551291 PMCID: PMC8491098.

2. Xingyao Li, Chunfang Gu, Sarah Hostachy, Soumyadip Sahu, Christopher Wittwer, Henning J. Jessenc, Dorothea Fiedler, Huanchen Wang, and Stephen B. Shears. Control of XPR1-dependent cellular phosphate efflux by InsP8 is an exemplar for functionally - exclusive inositol pyrophosphate signaling. PNAS. 2020 Feb 18. PubMed PMID: 32019887. **Paper highlighted as a “paper of the month” by the NIEHS factor. 3. Soumyadip Sahu, Zhenzhen Wang, Xinfu Jiao, Chunfang Gu, Nikolaus Jork, Christopher Wittwer, Xingyao Li, Sarah Hostachy, Dorothea Fiedler, Huanchen Wang, Henning J Jessen, Megerditch Kiledjian, Stephen B Shears. InsP7 is a small-molecule regulator of NUDT3-mediated mRNA decapping and processing-body dynamics. PNAS. 2020 Aug 11. PMID: 32727897 PMCID: PMC7431097.

4. Xingyao Li, Guo M, Cai L, Du T, Liu Y, Ding HF, Wang H, Zhang J, Chen X, Yan C. Competitive ubiquitination activates the tumor suppressor p53. Cell Death differentiation. 2019 Dec 2. PubMed PMID: 31796886. 5. Randall TA, Gu C, Xingyao Li, Wang H, Shears SB. A two-way switch for inositol pyrophosphate signaling: Evolutionary history and biological significance of a unique, bifunctional kinase/phosphatase. Adv Biol Regul. 2019 Nov 14. PubMed PMID: 31776069.

6. Cui H *, Xingyao Li*, Han C, Wang QE, Wang H, Ding HF, Zhang J, Yan C. The Stress- responsive Gene ATF3 Mediates Dichotomous UV Responses by Regulating the Tip60 and p53 Proteins. J Biol Chem. 2016 May 13;291(20):10847-57. PubMed PMID: 26994140; PubMed Central PMCID: PMC4865929.

7. Zhao J *, Xingyao Li *, Guo M, Yu J, Yan C. The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation. BMC Genomics. 2016 May 4;17: 335. PubMed PMID: 27146783; PubMed Central PMCID: PMC4857411.

8. Kong LM, Feng T, Wang YY, Xingyao Li, Ye ZN, An T, Qing C, Luo XD, Li Y. Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell in vitro and in vivo targeting Wnt signaling. Oncotarget. 2016 Mar 1;7(9):10203-14. PMID: 26862734 PMCID: PMC4891114

9. Xingyao Li, Bai B, Liu L, Ma P, Kong L, Yan J, Zhang J, Ye Z, Zhou H, Mao B, Zhu H, Li Y. Novel β-carbolines against colorectal cancer cell growth via inhibition of Wnt/β-catenin signaling. Cell Death Discov. 2015;1: 15033. PMID: 27551464 PMCID: PMC4979417 9

Xingyao Li, Ph.D.

10. Qin ZB, Zhang J, Wu XD, He J, Ding LF, Peng LY, Xingyao Li, Li Y, Deng L, Guo YD, Zhao QS. Sesquiterpenoids from Tussilago farfara and their inhibitory effects on nitric oxide production. Planta Med. 2014 Jun;80(8-9):703-9. PMID: 249*****-**. Bai B, Xingyao Li, Liu L, Li Y, Zhu HJ. Syntheses of novel β-carboline derivatives and the activities against five tumor-cell lines. Bioorg Med Chem Lett. 2014 Jan 1;24(1):96-8. PMID:24345445

12. Xingyao Li, Pu J, Jiang S, Su J, Kong L, Mao B, Sun H, Li Y. Henryin, an ent-kaurane diterpenoid, inhibits Wnt signaling through interference with β-catenin/TCF4 interaction in colorectal cancer cells. PLoS One. 2013;8(7). PubMed PMID: 23844215. 13. Xingyao Li, Wang Y, Yuan C, Hao X, Li Y. A reporter gene system for screening inhibitors of Wnt signaling pathway. Natural Products and Bioprospecting. 2013 February; 3(1):24-28.

14. Liang CQ, Shi YM, Xingyao Li, Luo RH, Li Y, Zheng YT, Zhang HB, Xiao WL, Sun HD. Kadcotriones A-C: tricyclic triterpenoids from Kadsura coccinea. J Nat Prod. 2013 Dec 27;76(12):2350-4. PubMed PMID: 24299567.

15. Wu X, Wang L, He J, Xingyao Li, Dong L, Gong X, Gao X, Song L, Li Y, Peng L, Zhao Q. Two New Indole Alkaloids from Emmenopterys henryi. Helvetica Chimica Acta. 2013 December; 96(12):2207-2213.

16. Wu XD, He J, Xingyao Li, Dong LB, Gong X, Gao X, Song LD, Li Y, Peng LY, Zhao QS. Triterpenoids and steroids with cytotoxic activity from Emmenopterys henryi. Planta Med. 2013 Sep;79(14):1356-61. PubMed PMID: 23881457.

17. Bao MF, Yan JM, Cheng GG, Xingyao Li, Liu YP, Li Y, Cai XH, Luo XD. Cytotoxic indole alkaloids from Tabernaemontana divaricata. J Nat Prod. 2013 Aug 23;76(8):1406-12. PubMed PMID: 23944995.

18. Feng T, Li Z, Yin X, Dong Z, Wang G, Xingyao Li, Li Y, Liu J. New benzene derivatives from cultures of ascomycete Daldinia concentrica. Natural Products and Bioprospecting. 2013 August; 3(4):150-153.

19. Su J, Zhao P, Kong L, Xingyao Li, Yan J, Zeng Y, Li Y. Trichothecin induces cell death in NF-κB constitutively activated human cancer cells via inhibition of IKKβ phosphorylation. PLoS One. 2013;8(8). PubMed PMID: 23936501.

20. Wu XD, He J, Xingyao Li, Dong LB, Gong X, Song LD, Li Y, Peng LY, Zhao QS. Diterpenoids from the twigs and leaves of Fokienia hodginsii. J Nat Prod. 2013 Jun 28;76(6):1032-8. PubMed PMID: 23691952.

10

Xingyao Li, Ph.D.

21. Liu W, Su J, Jiang J, Xingyao Li, Ye Q, Zhou H, Chen J, Li Y. Two mixed-NH3/amine platinum (II) anticancer complexes featuring a dichloroacetate moiety in the leaving group. Sci Rep. 2013; 3: 2464. PubMed PMID: 23955304; PubMed Central PMCID: PMC3746205.

22. Yuan CM, Zhang Y, Tang GH, Li Y, He HP, Li SF, Hou L, Xingyao Li, Di YT, Li SL, Hua HM, Hao XJ. Cytotoxic limonoids from Melia azedarach. Planta Med. 2013 Jan;79(2):163- 8. Epub 2012 Dec 18. PubMed PMID: 23250810.

23. Luo Z, Wang F, Zhang J, Xingyao Li, Zhang M, Hao X, Xue Y, Li Y, Horgen FD, Yao G, Zhang Y. Cytotoxic alkaloids from the whole plants of Zephyranthes candida. J Nat Prod. 2012 Dec 28;75(12):2113-20. PubMed PMID: 23190013; PubMed Central PMCID: PMC3580115.

24. Liang CQ, Shi YM, Luo RH, Xingyao Li, Gao ZH, Li XN, Yang LM, Shang SZ, Li Y, Zheng YT, Zhang HB, Xiao WL, Sun HD. Kadcoccitones A and B, two new 6/6/5/5-fused tetracyclic triterpenoids from Kadsura coccinea. Org Lett. 2012 Dec 21;14(24):6362-5. PubMed PMID: 23230829.

25. Liu L, Li Z, Dong Z, Xingyao Li, Su J, Li Y, Liu J. Two novel fomannosane-type sesquiterpenoids from the culture of the basidiomycete Agrocybe salicacola. Natural Products and Bioprospecting. 2012 June; 2(3):130-132. 26. Li SF, Zhang Y, Li Y, Xingyao Li, Kong LM, Tan CJ, Li SL, Di YT, He HP, Hao XJ. β- Carboline alkaloids from the leaves of Trigonostemon lii Y.T. Chang. Bioorg Med Chem Lett. 2012 Mar 15;22(6):2296-9. PubMed PMID: 22342628. 27. Huang SZ, Zhang XJ, Xingyao Li, Kong LM, Jiang HZ, Ma QY, Liu YQ, Hu JM, Zheng YT, Li Y, Zhou J, Zhao YX. Daphnane-type diterpene esters with cytotoxic and anti-HIV-1 activities from Daphne acutiloba Rehd. Phytochemistry. 2012 Mar;75:99-107. PubMed PMID: 22196934.

28. Liu YP, Li Y, Cai XH, Xingyao Li, Kong LM, Cheng GG, Luo XD. Melodinines M-U, cytotoxic alkaloids from Melodinus suaveolens. J Nat Prod. 2012 Feb 24;75(2):220-4. PubMed PMID: 22260257.

29. Tian LW, Xu M, Li Y, Xingyao Li, Wang D, Zhu HT, Yang CR, Zhang YJ. Phenolic compounds from the branches of Eucalyptus maideni. Chem Biodivers. 2012 Jan;9(1):123-30. PubMed PMID: 22253109.

30. Huang SZ, Zhang XJ, Xingyao Li, Jiang HZ, Ma QY, Wang PC, Liu YQ, Hu JM, Zheng YT, Zhou J, Zhao YX. Phenols with anti-HIV activity from Daphne acutiloba. Planta Med. 2012 Jan;78(2):182-5. PubMed PMID: 21989641.

11

Xingyao Li, Ph.D.

31. Cheng J, He,,Juan,, Xingyao Li, Wu X, Shao L, Dong L, Deng X, Gao X, Yan L, Cheng X, Li Y, Zhao Q. Three New Sucrose Fatty Acid Esters from Equisetum hiemale L. Helvetica Chimica Acta. 2012; 95(7):1158–1163.

32. He F, Xingyao Li, Yang G, Li X, Luo X, Zou J, Li Y, Xiao W, Sun H. Nortriterpene constituents from Schisandra sphenanthera. Tetrahedron. 2012 January; 68(2):440-446. 33. Wang LQ, Wu MM, Liu JP, Li Y, Hua Y, Wang YY, Xingyao Li, Chen YG, Wang JH. Five new diarylpropan-1-ols from Combretum yunnanense. Planta Med. 2011 Nov;77(16):1841-4. PubMed PMID: 21674439.

34. Liu L, Zhang L, Feng T, Li Z, Dong Z, Xingyao Li, Su J, Li Y, Liu J. Unusual illudin-type sesquiterpenoids from cultures of Agrocybe salicacola. Natural Products and Bioprospecting. 2011 October; 1(2):87-92.

35. Liu JQ, Wang CF, Xingyao Li, Chen JC, Li Y, Qiu MH. One new pregnane glycoside from the seeds of cultivated Brucea javanica. Arch Pharm Res. 2011 Aug;34(8):1297-300. PubMed PMID: 21910051.

36. Li L, Ni W, Xingyao Li, Hua Y, Fang PL, Kong LM, Pan LL, Li Y, Chen CX, Liu HY. Taccasubosides A-D, four new steroidal glycosides from Tacca subflabellata. Steroids. 2011 Sep-Oct;76(10-11):1037-42. PubMed PMID: 21515300. 37. Zhu F, Di YT, Xingyao Li, Liu LL, Zhang Q, Li Y, Hao XJ, He HP. Neoclerodane diterpenoids from Scutellaria barbata. Planta Med. 2011 Sep;77(13):1536-41. PubMed PMID: 21360416.

38. Shi YM, Xingyao Li, Li XN, Luo X, Xue YB, Liang CQ, Zou J, Kong LM, Li Y, Pu JX, Xiao WL, Sun HD. Schicagenins A-C: three cagelike nortriterpenoids from leaves and stems of Schisandra chinensis. Org Lett. 2011 Aug 5;13(15):3848-51. PubMed PMID: 21714531. 39. Dong L, He J, XingyaoLi, Wu X, Deng X, Xu G, Peng L, Zhao Y, Li Y, Gong X, Zhao Q. Chemical constituents from the aerial parts of Musella lasiocarpa. Natural Products and Bioprospecting. 2011 August; 1(0):41-47.

40. Bai B, Xingyao Li, Li Y, Zhu HJ. Design, synthesis and cytotoxic activities of novel β- amino alcohol derivatives. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2302-4. PubMed PMID: 21397498.

41. Wu MM, Wang LQ, Hua Y, Chen YG, Wang YY, Xingyao Li, Li Y, Li T, Yang XY, Tang ZR. New chalcone and dimeric chalcones with 1,4-p-benzoquinone residue from Combretum yunnanense. Planta Med. 2011 Mar;77(5):481-4. PubMed PMID: 21053158.

Contact this candidate